Navigation Links
Patrick J. Sullivan Elected to Gen-Probe Board of Directors
Date:9/20/2010

SAN DIEGO, Sept. 20 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that Patrick Sullivan, former chairman, president and chief executive officer of Cytyc Corporation, has been elected to its board of directors.  Gen-Probe's board now has 10 members, including eight independent directors.

"We are delighted that Pat has agreed to join Gen-Probe's already strong board," said Hank Nordhoff, the Company's chairman.  "We expect to benefit greatly from his experiences leading a multi-billion-dollar growth company, and from his deep knowledge of diagnostics and women's health."

Mr. Sullivan, 58, joined Cytyc in 1991 as vice president, sales and marketing.  He became president, CEO and a director in 1994, and added the chairman's title in 2002.  He remained in those roles until the company's merger with Hologic in 2007.  Mr. Sullivan now leads Constitution Medical Investors, a Boston-based private investment firm in partnership with Warburg Pincus, and is also a director of PerkinElmer.  He graduated with distinction from the U.S. Naval Academy and earned an M.B.A., also with distinction, from Harvard University.

About Gen-ProbeGen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe has approximately 27 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening.  Gen-Probe is headquartered in San Diego and employs approximately 1,300 people. For more information, go to www.gen-probe.com.

Caution Regarding Forward-Looking StatementsAny statements in this press release about our expectations, beliefs, plans, objectives, assumptions, future events or performance are not historical facts and are forward-looking statements.  These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would.  Forward-looking statements are not guarantees of performance.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that Gen-Probe may not be able to retain its key employees and directors.  For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and all subsequent periodic reports.  We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of subsequent events.Contact:Michael Watts

Vice president, investor relations and corporate communications

858-410-8673
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AAIPharma Services Corp. Names Patrick Walsh Chief Executive Officer
2. Patrick J. Zenner Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
3. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
4. Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution
5. Low Installation Rates in Retail Pharmacies Across Europe Increase the Growth Potential of the Pharmacy Automation Systems Market, Finds Frost & Sullivan
6. Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products
7. U.S. Ambulatory Electronic Health Record Market Presents Significant Opportunities and Risks for Vendors, Finds Frost & Sullivan
8. Increasing Potential for RIS-driven PACS Modules in Europe, Finds Frost & Sullivan
9. Frost & Sullivan Recognizes QRxPharma for Innovative Pain Relief Product MoxDuo
10. Rising Burden of Diseases Drives the Pharmaceutical Industry in East Africa, Says Frost & Sullivan
11. Frost & Sullivan: Innovative Products and Technologies Strengthen U.S. Spinal Surgery Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
Breaking Medicine Technology:
(Date:4/25/2017)... San Jose, CA (PRWEB) , ... April 25, ... ... in cross-screen access, support, and collaboration, announces Mirroring360 Pro . This new ... providing a comprehensive collaboration experience for education and business. , Mirroring360 Pro enables ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... CFOs and HR decision-makers are preparing for how his administration could impact the ... provide insight into what changes are most likely to make it through Congress. ...
(Date:4/25/2017)... Vegas, NV (PRWEB) , ... April 25, 2017 ... ... can now choose a modern procedure that achieves results in a fraction of ... in Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving multi-billion ... head shops –can’t help but be heartened by the industry’s current surge. But another ... described as “skunk smell.” At last they can simply, safely and effectively end ...
(Date:4/25/2017)... ... 25, 2017 , ... There is no better place in South Florida to ... in the May issue of Consumer Reports focused on heart health. , The ... during and after coronary bypass and aortic valve replacement procedures. , Consumer Reports ...
Breaking Medicine News(10 mins):